About 50% of patients with CLL/SLL have high-risk molecular features limiting effectiveness of certain treatments; a blood test can identify these features and help guide which therapy is most likely ...

A new bone marrow test can help doctors predict risk of leukemia relapse The test might double survival rates by predicting a relapse up to three months earlier than standard care The test looks for ...

A two-time breast cancer survivor who was diagnosed with chronic lymphocytic leukemia in 2020 discussed her belief in the power of minimal residual disease testing. Two-time breast cancer survivor Sue ...

New research assessing the efficacy of optical genome mapping (OGM) in a group of patients with acute leukemia has ...

Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with ...

Key Takeaways A highly sensitive DNA test can detect hidden leukemia cells that predict if a patient’s cancer is likely to ...

Domain adaptation may be a novel creative solution to predict infection risk in patients with chronic lymphocytic leukemia ...

Identification of recurrent genetic abnormalities is important for disease evaluation, optimal risk stratification and treatment planning. Testing for recurrent genetic abnormalities should be ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

The Test Before Treat campaign highlights how a patient’s genetic profile can change over time and encourages the use of a blood test to identify mutations to provide important insights into disease ...